Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

Dimopoulos M. A., Sonneveld P., Rodriguez-Otero P., Quach H., Ho P. J., BEKSAÇ M., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024 (SCI-Expanded, Scopus)

• Publication Type: Article / Abstract
• Publication Date: 2024
• Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
• Ankara University Affiliated: Yes